ATE228121T1 - Neues salz - Google Patents

Neues salz

Info

Publication number
ATE228121T1
ATE228121T1 AT98925993T AT98925993T ATE228121T1 AT E228121 T1 ATE228121 T1 AT E228121T1 AT 98925993 T AT98925993 T AT 98925993T AT 98925993 T AT98925993 T AT 98925993T AT E228121 T1 ATE228121 T1 AT E228121T1
Authority
AT
Austria
Prior art keywords
new salt
salt
new
Prior art date
Application number
AT98925993T
Other languages
English (en)
Inventor
Hakan Nyqvist
Daniel D Sohn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE228121T1 publication Critical patent/ATE228121T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
AT98925993T 1997-05-30 1998-05-15 Neues salz ATE228121T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702066A SE510305C2 (sv) 1997-05-30 1997-05-30 Nytt salt
PCT/SE1998/000907 WO1998054166A1 (en) 1997-05-30 1998-05-15 A new salt

Publications (1)

Publication Number Publication Date
ATE228121T1 true ATE228121T1 (de) 2002-12-15

Family

ID=20407187

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98925993T ATE228121T1 (de) 1997-05-30 1998-05-15 Neues salz

Country Status (33)

Country Link
US (2) US6858645B2 (de)
EP (1) EP0984952B1 (de)
JP (1) JP3554338B2 (de)
KR (1) KR20010013127A (de)
CN (1) CN1198814C (de)
AR (1) AR012751A1 (de)
AT (1) ATE228121T1 (de)
AU (1) AU729301B2 (de)
BG (1) BG64051B1 (de)
BR (1) BR9809519A (de)
CA (1) CA2291732C (de)
DE (1) DE69809547T2 (de)
DK (1) DK0984952T3 (de)
EE (1) EE03874B1 (de)
ES (1) ES2187030T3 (de)
HU (1) HUP0001878A3 (de)
ID (1) ID23794A (de)
IL (1) IL133234A (de)
IS (1) IS1943B (de)
MY (1) MY117960A (de)
NO (1) NO995853L (de)
NZ (1) NZ501075A (de)
PL (1) PL337181A1 (de)
PT (1) PT984952E (de)
RU (1) RU2193560C2 (de)
SE (1) SE510305C2 (de)
SK (1) SK282755B6 (de)
TR (1) TR199902926T2 (de)
TW (1) TW510899B (de)
UA (1) UA53720C2 (de)
WO (1) WO1998054166A1 (de)
YU (1) YU62499A (de)
ZA (1) ZA984486B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
KR20050040921A (ko) * 2002-08-15 2005-05-03 와이어쓰 체온조절 기능장애 치료를 위한 5ＨＴ2ａ 수용체의 항진제
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
WO2007134198A1 (en) * 2006-05-11 2007-11-22 Johnson Controls- Saft Advanced Power Solutions Llc Modular battery system
JP5163931B2 (ja) * 2007-03-08 2013-03-13 株式会社リコー 定着装置及び画像形成装置
EP2065385A1 (de) * 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stabiles Kristallinsalz aus (R)-3-Fluorphenyl-3,4,5-Trifluorbenzylcarbaminsäure 1-Azabiciyclo [2.2.2]oct-3-yl Ester
CN103833713B (zh) * 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶iii型、其制法和其药物组合物与用途
TR201901931T4 (tr) * 2013-04-26 2019-03-21 Sanofi Sa 5-kloro-tiyofen-2-karboksilik asit [(s)-2-[metil-3-(2-okso-pirolidin-1-il)-benzensülfonilamino]-3-(4-metil-piperazin-1 -il)-3-okso-propril]amidin tartrat tuzu.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62231B1 (en) * 1987-12-24 1995-01-11 Wyeth John & Brother Ltd Heterocyclic compounds
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
US5616610A (en) * 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
RU2047614C1 (ru) * 1992-06-15 1995-11-10 Джон Вайс энд Бразер Лимитед Гетероциклические соединения, или их фармацевтически приемлемые аддитивные соли кислоты, или n-оксид гетероциклического соединения, или его аддитивная соль кислоты
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
IT1282705B1 (it) 1996-02-28 1998-03-31 Recordati Chem Pharm Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria

Also Published As

Publication number Publication date
US20050085532A1 (en) 2005-04-21
EP0984952A1 (de) 2000-03-15
HUP0001878A2 (hu) 2001-05-28
KR20010013127A (ko) 2001-02-26
UA53720C2 (uk) 2003-02-17
DE69809547T2 (de) 2003-08-21
YU62499A (sh) 2002-06-19
TW510899B (en) 2002-11-21
US6858645B2 (en) 2005-02-22
BR9809519A (pt) 2000-06-20
IS1943B (is) 2004-08-13
HUP0001878A3 (en) 2002-04-29
IL133234A0 (en) 2001-03-19
SE510305C2 (sv) 1999-05-10
ZA984486B (en) 1998-11-30
AU7792398A (en) 1998-12-30
CN1198814C (zh) 2005-04-27
US20030109576A1 (en) 2003-06-12
SE9702066D0 (sv) 1997-05-30
EE9900549A (et) 2000-06-15
IS5270A (is) 1999-11-24
CN1258290A (zh) 2000-06-28
JP3554338B2 (ja) 2004-08-18
TR199902926T2 (xx) 2000-03-21
EE03874B1 (et) 2002-10-15
PL337181A1 (en) 2000-08-14
NO995853D0 (no) 1999-11-29
AU729301B2 (en) 2001-02-01
ID23794A (id) 2000-05-11
JP2002501527A (ja) 2002-01-15
SK282755B6 (sk) 2002-12-03
ES2187030T3 (es) 2003-05-16
CA2291732A1 (en) 1998-12-03
DK0984952T3 (da) 2003-02-24
BG64051B1 (bg) 2003-11-28
MY117960A (en) 2004-08-30
SE9702066L (sv) 1998-12-01
SK159499A3 (en) 2000-10-09
PT984952E (pt) 2003-03-31
BG103949A (en) 2000-07-31
CA2291732C (en) 2003-12-30
EP0984952B1 (de) 2002-11-20
WO1998054166A1 (en) 1998-12-03
HK1025575A1 (en) 2000-11-17
NO995853L (no) 2000-01-31
NZ501075A (en) 2001-08-31
IL133234A (en) 2004-05-12
AR012751A1 (es) 2000-11-08
RU2193560C2 (ru) 2002-11-27
DE69809547D1 (de) 2003-01-02

Similar Documents

Publication Publication Date Title
EE200000044A (et) Uued ühendid
TR199802106A3 (tr) Sübstitüe edilmis izokinolin-3-karbon asidi amidleri.
ATE250583T1 (de) Substituierte 3-cyanochinoline
DE59700718D1 (de) Fahrschemel
PT1036083E (pt) Novos 9a-azalidos
DE69809547D1 (de) Neues salz
DE59804098D1 (de) Verdampferanordnung
ATA146896A (de) Neues kristallines salz von cefixim
DK0983266T3 (da) Hidtil ukendte tetrahydrosioquinolinthiophencarboximidamider
ATE241275T1 (de) Phosphoniumsalz-zusammensetzung
EP0949331A4 (de) Etablierte Mikrogliazellen
ATE244705T1 (de) Substituierte 4-benzoyl-pyrazole
NO993386L (no) Elektrode
FI972138A0 (fi) Returtraog i bestrykningsanordning
SE9702517D0 (sv) Anfästning
UA85U (uk) Ідентифікатор
KR970021293U (ko) 특허 출원서 행정 양식
SE9702378D0 (sv) New compounds
SE9702747D0 (sv) New compounds
SE9704839D0 (sv) New compounds
SE9702696D0 (sv) New compounds
SE9704838D0 (sv) New compounds
SE9704837D0 (sv) New compounds
SE9703225D0 (sv) new compounds
SE9702746D0 (sv) New compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0984952

Country of ref document: EP

REN Ceased due to non-payment of the annual fee